Consensus Report from Oncology Advisory Board Meeting

Contents Preface 5 Synopsis 6 Oncologists' Perspective on Kidney Injury in Cancer Patients 7 Burden of Cancer in India Use of Imaging with Contrast in Oncology Protecting Kidney in Cancer Patients Multiple Risk Factors for AKI in Cancer Patients Nephrologists’ Viewpoint on Recent Advances in CI-AKI 10 Burden of Nephrotoxicity Terminology of CI-AKI Biomarkers in CI-AKI Renal Functional Reserve The Optimal Use of Contrast Media in Cancer Patients - Radiologists' Perspective 14 Introduction Computed Tomography (CT) Protocols Iterative Reconstruction (IR) Importance of Iodine Delivery Rate Safety and Tolerability Contrast Medium Osmolality Contrast Medium Viscosity Hydration Protocol Drug Interactions to be Avoided Route of Contrast Administration and Risk of CI-AKI Review of Clinical Evidence of Contrast Induced-Acute Kidney Injury (CI-AKI) in Oncology Settings 17 Clinical Evidence of AKI Risk in Cancer Patients Burden of AKI in Oncology Patients – Does the Choice of Contrast Media Matter? 20 Structures and Properties of CM Is Isosmolar Contrast Medium (IOCM) Better Than Low Osmolar Contrast Medium (LOCM) – Clinical Evidence Important Physicochemical Characteristics of CT CM and Their Clinical Relevance Safety and Tolerability of Iodixanol in Clinical Settings Note on International Guidelines on AKI Management 24 Expert Opinion/Recommendations to Prevent CI-AKI in Oncology Patients 26 Do’s and Don’ts Before, During, and After Contrast-Based Imaging to Prevent CI-AKI 27